Whittier Trust Co. Cuts Position in Hologic, Inc. $HOLX

Whittier Trust Co. cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 23.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 697 shares of the medical equipment provider’s stock after selling 213 shares during the quarter. Whittier Trust Co.’s holdings in Hologic were worth $45,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. Victory Capital Management Inc. increased its holdings in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after acquiring an additional 1,692,177 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Hologic by 473.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. Nuance Investments LLC lifted its holdings in shares of Hologic by 623.7% during the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after purchasing an additional 931,920 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after purchasing an additional 764,573 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Hologic during the 1st quarter valued at $30,317,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HOLX. Mizuho lowered Hologic from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $70.00 to $78.00 in a report on Thursday. Raymond James Financial lowered Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday. Argus increased their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Stephens lowered Hologic from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $78.00 to $76.00 in a research note on Wednesday. Finally, BTIG Research restated a “neutral” rating on shares of Hologic in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $79.23.

Hologic Stock Performance

Shares of HOLX stock opened at $73.99 on Friday. The firm has a market capitalization of $16.46 billion, a price-to-earnings ratio of 30.70, a price-to-earnings-growth ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business has a fifty day moving average of $67.65 and a 200 day moving average of $63.95. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.88% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.